<SEC-DOCUMENT>0001193125-25-288343.txt : 20251119
<SEC-HEADER>0001193125-25-288343.hdr.sgml : 20251119
<ACCEPTANCE-DATETIME>20251119172043
ACCESSION NUMBER:		0001193125-25-288343
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251119
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251119
DATE AS OF CHANGE:		20251119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Olema Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001750284
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				300409740
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39712
		FILM NUMBER:		251500259

	BUSINESS ADDRESS:	
		STREET 1:		780 BRANNAN STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94103
		BUSINESS PHONE:		(415) 651-3316

	MAIL ADDRESS:	
		STREET 1:		780 BRANNAN STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d46182d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:olma="http://olema.com/20251119" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-298">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-11-19_to_2025-11-19">0001750284</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="olma-20251119.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-11-19_to_2025-11-19"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001750284</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-19</xbrli:startDate> <xbrli:endDate>2025-11-19</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-309">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-11-19_to_2025-11-19" format="ixt:datemonthdayyearen" id="ixv-310">November&#160;19, 2025</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-311">Olema Pharmaceuticals, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-11-19_to_2025-11-19" format="ixt-sec:stateprovnameen" id="ixv-312">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-313">001-39712</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-314">30-0409740</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Commission<br/>File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt"/>
<td style="height:9.75pt" colspan="2"/>
<td style="height:9.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-315">780 Brannan Street</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-316">San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-11-19_to_2025-11-19" format="ixt-sec:stateprovnameen" id="ixv-317">California</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-318">94103</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <span style="white-space:nowrap"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-319">415</ix:nonNumeric>-<ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-320">651-3316</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-11-19_to_2025-11-19" format="ixt-sec:boolballotbox" id="ixv-321">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-11-19_to_2025-11-19" format="ixt-sec:boolballotbox" id="ixv-322">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-11-19_to_2025-11-19" format="ixt-sec:boolballotbox" id="ixv-323">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-11-19_to_2025-11-19" format="ixt-sec:boolballotbox" id="ixv-324">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center"><br/>Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-325">Common Stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-326">OLMA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-11-19_to_2025-11-19" format="ixt-sec:exchnameen" id="ixv-327">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-11-19_to_2025-11-19" format="ixt-sec:boolballotbox" id="ixv-328">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Follow-On</span> Public Offering </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November&#160;18, 2025, Olema Pharmaceuticals, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with TD Securities (USA) LLC, as representative of the several underwriters named therein (collectively, the &#8220;Underwriters&#8221;), relating to the issuance and sale in a public offering of 10,000,000 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), at a price to the public of $19.00 per share of Common Stock. The closing of the offering is expected to occur on November&#160;20, 2025, subject to the satisfaction of customary closing conditions. In addition, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to 1,500,000 additional shares of Common Stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds to the Company from the offering will be approximately $190.0&#160;million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, and assuming no exercise of the Underwriters&#8217; option to purchase additional shares. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement and may be subject to limitations agreed upon by such parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering is being made pursuant to the Company&#8217;s effective shelf registration statement on Form <span style="white-space:nowrap">S-3</span> and accompanying prospectus (File <span style="white-space:nowrap">No.&#160;333-284146),</span> filed with the Securities and Exchange Commission, and a prospectus supplement thereunder. A copy of the Underwriting Agreement is filed as Exhibit 1.1 to this report, and the foregoing description of the terms of the Underwriting Agreement does not purport to be complete and is qualified in their entirety by reference to such exhibits. A copy of the opinion of Cooley LLP relating to the legality of the issuance and sale of Common Stock in the offering is attached as Exhibit 5.1 hereto. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Forward Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Statements contained in this Current Report on Form <span style="white-space:nowrap">8-K</span> regarding matters that are not historical facts are &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act. Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;seek,&#8221; &#8220;upcoming,&#8221; &#8220;will,&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include, but are not limited to, the Company&#8217;s expectations with respect to the completion of the offering and the expected gross proceeds from the offering. Because such statements deal with future events and are based on Olema&#8217;s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Olema could differ materially from those described in or implied by the statements in this Current Report on Form <span style="white-space:nowrap">8-K.</span> These forward-looking statements are subject to risks and uncertainties, including, without limitation, those discussed in the section titled &#8220;Risk Factors&#8221; in Olema&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarter ended June&#160;30, 2025, and other filings and reports that Olema makes from time to time with the U.S. Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements, including in the event that actual results differ materially from those anticipated in the forward-looking statements. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br/>No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d46182dex11.htm">Underwriting Agreement by and between the Company and TD Securities (USA) LLC, as representative of the several underwriters named therein, dated November&#160;18, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d46182dex51.htm">Opinion of Cooley LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d46182dex51.htm">Consent of Cooley LLP (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Olema Pharmaceuticals, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: November&#160;19, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Shane Kovacs</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shane Kovacs</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Operating and Financial Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d46182dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXECUTION VERSION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Underwriting Agreement </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Olema
Pharmaceuticals, Inc. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10,000,000 Shares of Common Stock </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">November&nbsp;18, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representative of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">several
Underwriters listed </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o TD Securities (USA) LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 Vanderbilt Avenue, 11th Floor
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Olema Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), proposes to issue and sell to the several underwriters listed
in Schedule 1 hereto (the &#8220;Underwriters&#8221;), for whom you are acting as representative (the &#8220;Representative&#8221;), an aggregate of 10,000,000 shares of common stock, par value $ 0.0001 per share (the &#8220;Common Stock&#8221;), of
the Company (the &#8220;Underwritten Shares&#8221;). In addition, the Company proposes to sell, at the option of the Underwriters, up to an additional 1,500,000 shares of Common Stock of the Company (the &#8220;Option Shares&#8221;). The
Underwritten Shares and the Option Shares are herein referred to as the &#8220;Shares&#8221;. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the
&#8220;Stock&#8221;. In the event that the Company has only one subsidiary, then all references herein to &#8220;subsidiaries&#8221; of the Company shall be deemed to refer to such single subsidiary, <I>mutatis mutandis</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the several Underwriters concerning the purchase and sale of the Shares, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Registration Statement</U>. The Company has prepared and filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;)
under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#8220;Securities Act&#8221;), a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-284146),</FONT> including a prospectus, relating to certain securities, including shares of Common Stock, to be issued from time to time by the Company (the &#8220;Base Prospectus&#8221;). Such registration
statement, as amended at the time it became effective, including the information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effectiveness (&#8220;Rule 430 Information&#8221;), is referred to herein as the &#8220;Registration Statement&#8221;; and as used herein, the term &#8220;Preliminary Prospectus&#8221; means in
the Base Prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information and the preliminary prospectus supplement thereto dated November&nbsp;18, 2025 relating to the Shares in the form filed with
the Commission pursuant to Rule 424(b) under the Securities Act, and the term &#8220;Prospectus&#8221; means the Base Prospectus and the final prospectus supplement in the form first used (or made available upon request of purchasers pursuant to
Rule 173 under the Securities Act) in connection with confirmation of sales of the Shares. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the &#8220;Rule 462 Registration
Statement&#8221;), then any reference herein to the term &#8220;Registration Statement&#8221; shall be deemed to include such Rule 462 Registration Statement. Any reference in this underwriting agreement (this &#8220;Agreement&#8221;) to the
Registration Statement, the Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities
Act, as of the effective date of the Registration Statement or the date of the Preliminary Prospectus or the Prospectus, as the case may be, and any reference to &#8220;amend&#8221;, &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect
to the Registration Statement, the Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Securities Exchange Act of 1934, as amended, and the rules and regulations of the
Commission thereunder (collectively, the &#8220;Exchange Act&#8221;) that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Registration Statement and
the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Applicable Time (as defined below), the Company had prepared the following information (collectively
with the pricing information set forth on Annex A, the &#8220;Pricing Disclosure Package&#8221;): the Preliminary Prospectus dated November&nbsp;18, 2025 and each &#8220;free-writing prospectus&#8221; (as defined pursuant to Rule 405 under the
Securities Act) listed on Annex A hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8220;Applicable Time&#8221; means 9:50 P.M., New York City time, on November&nbsp;18, 2025.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase of the Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to issue and sell the Underwritten Shares to the several Underwriters as provided in this underwriting agreement (this
&#8220;Agreement&#8221;), and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per Share of
$17.86 (the &#8220;Purchase Price&#8221;) from the Company the respective number of Underwritten Shares set forth opposite such Underwriter&#8217;s name in Schedule 1 hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company agrees to issue and sell the Option Shares to the several Underwriters as provided in this Agreement, and the
Underwriters, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the option to purchase, severally and not jointly, from the Company the Option Shares at the
Purchase Price less an amount per Share equal to any dividends or distributions declared by the Company and payable on the Underwritten Shares but not payable on the Option Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any Option Shares are to be purchased, the number of Option Shares to be purchased by
each Underwriter shall be the number of Option Shares which bears the same ratio to the aggregate number of Option Shares being purchased as the number of Underwritten Shares set forth opposite the name of such Underwriter in Schedule 1 hereto (or
such number increased as set forth in Section&nbsp;10 hereof) bears to the aggregate number of Underwritten Shares being purchased from the Company by the several Underwriters, subject, however, to such adjustments to eliminate any fractional Shares
as the Representative in its sole discretion shall make. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriters may exercise the option to purchase Option Shares at any time
in whole, or from time to time in part, on or before the thirtieth day following the date of the Prospectus, by written notice from the Representative to the Company. Such notice shall set forth the aggregate number of Option Shares as to which the
option is being exercised and the date and time when the Option Shares are to be delivered and paid for, which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than
the tenth full business day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions of Section&nbsp;10 hereof). Any such notice shall be given at least two business days prior
to the date and time of delivery specified therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company understands that the Underwriters intend to make a public offering of
the Shares, and initially to offer the Shares on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Shares to or through any affiliate of an Underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Payment for the Shares shall be made by wire transfer in immediately available funds to the account specified by the Company to the
Representative in the case of the Underwritten Securities, at the offices of Davis Polk&nbsp;&amp; Wardwell LLP, 900 Middlefield Road, Redwood City, California 94063 at 10:00 A.M., New York City time, on November&nbsp;20, 2025, or at such other time
or place on the same or such other date, not later than the fifth business day thereafter, as the Representative and the Company may agree upon in writing or, in the case of the Option Shares, on the date and at the time and place specified by the
Representative in the written notice of the Underwriters&#8217; election to purchase such Option Shares. The time and date of such payment for the Underwritten Shares is referred to herein as the &#8220;Closing Date&#8221;, and the time and date for
such payment for the Option Shares, if other than the Closing Date, is herein referred to as the &#8220;Additional Closing Date&#8221;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payment for the Shares to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made against delivery
to the Representative for the respective accounts of the several Underwriters of the Shares to be purchased on such date or the Additional Closing Date, as the case may be, with any transfer taxes payable in connection with the sale of such Shares
duly paid by the Company. Delivery of the Shares shall be made through the facilities of The Depository Trust Company (&#8220;DTC&#8221;) unless the Representative shall otherwise instruct. The certificates for the Shares will be made available for
inspection by the Representative on the business day prior to the Closing Date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The Company acknowledges and agrees that the Representative and the other Underwriters
are acting solely in the capacity of an arm&#8217;s length contractual counterparty to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining the terms of the offering) and not as a financial
advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, neither the Representative nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory
matters in any jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither the
Representative nor the other Underwriters shall have any responsibility or liability to the Company with respect thereto. Any review by the Representative and the other Underwriters of the Company, the transactions contemplated hereby or other
matters relating to such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Underwriter that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Preliminary Prospectus.</I> No order preventing or suspending the use of the Preliminary Prospectus has been issued by
the Commission, and the Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Securities Act, and the Preliminary Prospectus did not, at the time of filing
thereof, contain any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the
Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the
Representative expressly for use in the Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Pricing Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing
Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to
the Company in writing by such Underwriter through the Representative expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information
described as such in Section&nbsp;7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is
required to be included in the Prospectus has been omitted therefrom. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Issuer Free Writing Prospectus. </I>Other than the Registration
Statement, the Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not
prepare, make, use, authorize, approve or refer to any &#8220;written communication&#8221; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares (each such communication by
the Company or its agents and representatives (other than a communication referred to in clause (i)&nbsp;below) an &#8220;Issuer Free Writing Prospectus&#8221;) other than (i)&nbsp;any document not constituting a prospectus pursuant to
Section&nbsp;2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road show and any other written communications approved in writing in advance by the
Representative. Each such Issuer Free Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to the extent
required thereby) and does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, and, when taken together with the Preliminary Prospectus accompanying, or delivered prior to delivery of or filed
prior to the first use of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in
each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representative expressly for use
in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials. </I>The
Company (i)&nbsp;has not engaged in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications other than
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the consent of the Representative (x)&nbsp;with entities that are qualified institutional buyers (&#8220;QIBs&#8221;) within the
meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act (&#8220;IAIs&#8221;) and otherwise in compliance with the
requirements of Section&nbsp;5(d) of the Securities Act or (y)&nbsp;with entities that the Company reasonably believed to be QIBs or IAIs and otherwise in compliance with the requirements of Rule 163B under the Securities Act and (ii)&nbsp;has not
authorized anyone other than the Representative to engage in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has not distributed or approved for distribution any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications in connection with the offering of the Shares other than those listed on Annex B hereto. &#8220;Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#8221; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the
meaning of Rule 405 under the Securities Act. Any individual Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, complied in all material respects with the applicable requirements of the
Securities Act, and when taken together with the Pricing Disclosure Package as of the Applicable Time, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a
material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Registration Statement and Prospectus.</I> The Registration Statement has been declared effective by the Commission. No
order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the Company or related to the offering of the Shares
has been initiated or, to the knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any such post-effective
amendment complied and will comply in all material respects with the applicable requirements of the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated
therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date and as of the Additional Closing Date, as the case may be, the
Prospectus will comply in all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any
Underwriter furnished to the Company in writing by such Underwriter through the Representative expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only
such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Incorporated Documents</I>. The documents incorporated by reference in the Registration Statement, the Prospectus and
the Pricing Disclosure Package, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state a
material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus or
the Pricing Disclosure Package, when such documents were filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Financial Statements.</I> The financial statements (including the
related notes thereto) of the Company and its consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable
requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material respects the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations
and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles (&#8220;GAAP&#8221;) in the United States applied on a consistent basis
throughout the periods covered thereby, except in the case of unaudited interim financial statements, which are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain certain footnotes as permitted by the
applicable rules of the Commission, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects the information required to be stated therein; and the other financial
information included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in
all material respects the information shown thereby; and the pro forma financial information and the related notes thereto have been prepared in accordance with the applicable requirements of the Securities Act and the Exchange Act, as applicable,
in all material respects, and the assumptions underlying such pro forma financial information are reasonable and are set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>No Material Adverse Change.</I> Since the date of the most recent financial statements of the Company included or
incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any change in the capital stock (other than the issuance of shares of Common Stock upon exercise of stock options
and warrants and vesting of other equity awards described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure Package and the Prospectus),
short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or
any development that would reasonably be expected to result in a material adverse change, in or affecting the business, properties, management, financial position, stockholders&#8217; equity, results of operations or prospects of the Company and its
subsidiaries taken as a whole; (ii)&nbsp;neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as
a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii)&nbsp;neither the Company nor any of its subsidiaries has sustained any loss or interference with
its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order
or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Organization and Good Standing.</I> The Company and each of its
subsidiaries have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their
respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they
are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position,
stockholders&#8217; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a &#8220;Material Adverse Effect&#8221;). The Company
does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21.1 to the Company&#8217;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the most
recently ended fiscal year other than (i)&nbsp;those subsidiaries not required to be listed on Exhibit 21.1 by Item 601 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Exchange Act and (ii)&nbsp;those subsidiaries formed since
the last day of the most recently ended fiscal year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Capitalization.</I> The Company has an authorized
capitalization as set forth or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued
and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights that have not been duly waived or satisfied; except as described in or
expressly contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including, without limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights that have not been
duly waived or satisfied), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement,
understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company
conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary
owned, directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and are owned directly or indirectly by the Company, free and clear of any
lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Stock Options. </I>With respect to the stock options (the
&#8220;Stock Options&#8221;) granted pursuant to the stock-based compensation plans of the Company and its subsidiaries (the &#8220;Company Stock Plans&#8221;), except to the extent not material, (i)&nbsp;each Stock Option intended to qualify as an
&#8220;incentive stock option&#8221; under Section&nbsp;422 of the Code (as defined below) so qualifies, (ii)&nbsp;each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be
effective by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes
or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all
other applicable laws and regulatory rules or requirements, including the applicable rules of the Nasdaq Global Select Market (the &#8220;Nasdaq Market&#8221;), and (iv)&nbsp;each such grant was properly accounted for in accordance with GAAP in the
financial statements (including the related notes) of the Company. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company of granting, Stock Options prior to, or otherwise coordinating the grant of
Stock Options with, the release or other public announcement of material information regarding the Company or its subsidiaries or their results of operations or prospects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Due Authorization.</I> The Company has full right, power and authority to execute and deliver this Agreement and to
perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly
taken. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Underwriting Agreement. </I>This Agreement has been duly authorized, executed and delivered by the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>The Shares. </I>The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company
and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform in all material respects to the descriptions thereof in the Registration Statement, the Pricing
Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights that have not been duly waived or satisfied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>[Reserved]</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>No Violation or Default.</I> Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its charter or <FONT
STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any
term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound
or to which any property or asset of the Company or any of its subsidiaries is subject; or (iii)&nbsp;in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority,
except, in the case of clauses (ii)&nbsp;and (iii) above, for any such default or violation that would not, individually or in the aggregate, have a Material Adverse Effect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>No Conflicts. </I>The execution, delivery and performance by the
Company of this Agreement, the issuance and sale of the Shares and the consummation by the Company of the transactions contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not (i)&nbsp;conflict with or result in a
breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right
or asset of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its
subsidiaries is bound or to which any property, right or asset of the Company or any of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar
organizational documents of the Company or any of its subsidiaries or (iii)&nbsp;result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in
the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <I>No Consents Required.</I> No consent, approval, authorization, order, registration or qualification of or with any court
or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares and the consummation by the Company of the transactions contemplated
by this Agreement, except for the registration of the Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority, Inc.
(&#8220;FINRA&#8221;) and under applicable state securities or blue sky laws in connection with the purchase and distribution of the Shares by the Underwriters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <I>Legal Proceedings.</I> There are no legal, governmental or regulatory investigations, actions, demands, claims, suits,
arbitrations, inquiries or proceedings (&#8220;Actions&#8221;) pending to which the Company or any of its subsidiaries is or may reasonably be expected to become a party or to which any property of the Company or any of its subsidiaries is or may be
the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, could reasonably be expected to have a Material Adverse Effect; to the knowledge of the Company, no such Actions are threatened or
contemplated by any governmental or regulatory authority or threatened by others; and (i)&nbsp;there are no current or pending Actions that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure
Package or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the
Securities </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Act to be filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the
Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t)
<I>Independent Accountants</I>. Ernst&nbsp;&amp; Young LLP, who have certified certain financial statements of the Company and its subsidiaries (including the related notes thereto) and supporting schedules filed with the Commission or contained or
incorporated by reference as a part of the Registration Statement, Prospectus and the Pricing Disclosure Package, is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and
regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act and the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <I>Title to Real and Personal Property</I>. The Company has good and marketable title in fee simple (in the case of real
property) to, or have valid rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims
and defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii)&nbsp;could not reasonably be expected, individually
or in the aggregate, to have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Intellectual Property.</I> Except as otherwise described in
the Registration Statement, the Pricing Disclosure or the Prospectus (i)&nbsp;the Company and its subsidiaries own or have the right to use all patent applications, patents, trademarks, trademark registrations, trademark applications, service marks,
service mark registrations, service mark applications, trade names, service names, Internet domain names and other source indicators, copyrights, copyright registrations, copyrightable works, databases, formulae,
<FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets, systems, procedures, proprietary or confidential information and all other intellectual property, industrial property and proprietary rights (including other unpatented and/or
unpatentable proprietary confidential information, systems, or procedures), and all goodwill associated with any of the foregoing (collectively, &#8220;Intellectual Property&#8221;), in each case used or held for use in, or necessary for the conduct
of their respective businesses as conducted or proposed to be conducted in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (ii)&nbsp;to the Company&#8217;s knowledge, the Company&#8217;s and its subsidiaries&#8217;
conduct of their respective businesses as currently conducted or as proposed to be conducted in the Registration Statement, the Pricing Disclosure Package or the Prospectus does not infringe, misappropriate or otherwise violate, and has not
infringed, misappropriated, or otherwise violated, any valid and enforceable Intellectual Property of any third party; (iii)&nbsp;there is no pending or, to the knowledge of the Company, threatened action, suit, proceeding or claim by any third
party (A)&nbsp;alleging that the Company or any of its subsidiaries has infringed, misappropriated or otherwise violated the Intellectual Property rights of any third party, or (B)&nbsp;challenging the inventorship, ownership, validity, scope or
enforceability of, or any rights of the Company or any of its subsidiaries in, any Intellectual Property owned by or licensed to the Company </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or any of its subsidiaries; (iv)&nbsp;no Intellectual Property owned by or exclusively licensed to the Company or any of its subsidiaries has been adjudged invalid or unenforceable and, to the
Company&#8217;s knowledge, all such Intellectual Property is valid and enforceable; (v)&nbsp;to the knowledge of the Company, no third party has infringed, misappropriated or otherwise violated any Intellectual Property owned by or exclusively
licensed to the Company or any of its subsidiaries; (vi)&nbsp;the Company and its subsidiaries have at all times taken reasonable steps in accordance with normal industry practice to maintain confidentiality of all Intellectual Property whose value
to the Company or its subsidiaries is contingent upon maintaining the confidentiality thereof, including by requiring employees, contractors, consultants and other third parties who receive such Intellectual Property to execute appropriate
agreements to maintain such confidentiality; and (vii)&nbsp;all current and former employees and consultants and other parties involved in the development of Intellectual Property for the Company or any of its subsidiaries have signed agreements
with the Company or its subsidiaries, pursuant to which the Company or its subsidiaries either (A)&nbsp;have obtained ownership of and are the exclusive owners of such Intellectual Property, or (B)&nbsp;have obtained a valid right to exploit such
Intellectual Property, sufficient for the conduct of their respective businesses as currently conducted or as proposed to be conducted in the Registration Statement, the Pricing Disclosure Package or the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <I>No Undisclosed Relationships</I>. No relationship, direct or indirect, exists between or among the Company or any of its
subsidiaries, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be described in each of the
Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <I>Investment Company Act</I>. The Company is not and, after giving effect to the offering and sale of the Shares and the
application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an &#8220;investment company&#8221; or an entity &#8220;controlled&#8221; by an
&#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#8220;Investment Company Act&#8221;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <I>Taxes.</I> The Company and its subsidiaries have filed all U.S. federal, state, local and foreign tax returns required
to be filed through the date hereof (except where the failure to file would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect) and have paid all taxes required to be paid thereon (except where the
failure to pay would not reasonably be expected to have a Material Adverse Effect, and except as are currently being contested in good faith and for which reserves required by GAAP have been created in the financial statements of the Company); and
except as otherwise disclosed in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no tax deficiency that has been determined adversely to the Company or any of its subsidiaries which has had (nor does
the Company nor any of its subsidiaries have any notice or knowledge of any tax deficiency which is expected to be determined adversely to the Company or its subsidiaries and which could reasonably be expected to have) a Material Adverse Effect.
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <I>Licenses and Permits.</I> The Company and its subsidiaries possess
all licenses, <FONT STYLE="white-space:nowrap">sub-licenses,</FONT> certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or
regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus,
including, without limitation, from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;), except where the failure to possess or make the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect; and except as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its subsidiaries has received notice of any revocation or modification of any such license, <FONT
STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit or authorization or has any reason to believe that any such license, <FONT STYLE="white-space:nowrap">sub-license,</FONT> certificate, permit or authorization will not be renewed in
the ordinary course, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <I>No Labor Disputes.</I> (i)&nbsp;No labor disturbance by or dispute with employees of the Company or any of its
subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and (ii)&nbsp;the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries&#8217;
principal suppliers, contractors or customers, except in the case of each of (i)&nbsp;and (ii) above, as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its
subsidiaries is a party to any collective bargaining agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <I>Certain Environmental Matters</I>. (i)&nbsp;The
Company and its subsidiaries (x)&nbsp;are in compliance with all, and have not violated any, applicable federal, state, local and foreign laws, rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable
requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#8220;Environmental Laws&#8221;); (y) have
received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and (z)&nbsp;have not
received notice of any actual or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic
substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;there are no costs or liabilities associated with Environmental Laws of or
relating to the Company or its subsidiaries, except in the case of each of (i)&nbsp;and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Effect; and (iii)&nbsp;except as described in each of the Pricing Disclosure Package and the Prospectus, (x)&nbsp;there is no proceeding that is pending, or that is known by the Company to be
contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which is the Company reasonably believes no monetary sanctions of $100,000
or more will be imposed, (y)&nbsp;the Company and its subsidiaries are not aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic
substances or wastes, pollutants or contaminants, that would reasonably be expected to have a Material Adverse Effect, and (z)&nbsp;none of the Company or its subsidiaries anticipates material capital expenditures relating to any Environmental Laws.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <I>Compliance with ERISA</I>. (i)&nbsp;Each employee benefit plan, within the meaning of Section&nbsp;3(3) of the
Employee Retirement Income Security Act of 1974, as amended (&#8220;ERISA&#8221;), for which the Company or any member of its &#8220;Controlled Group&#8221; (defined as any entity, whether or not incorporated, that is under common control with the
Company within the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m) or (o)&nbsp;of the Internal Revenue Code of 1986, as amended (the
&#8220;Code&#8221;)) would have any liability (each, a &#8220;Plan&#8221;) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the
Code; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption;
(iii)&nbsp;for each Plan that is subject to the funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards
(within the meaning of Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code) applicable to such Plan; (iv)&nbsp;no Plan is, or is reasonably expected to be, in &#8220;at risk status&#8221; (within the meaning of Section&nbsp;303(i) of ERISA)
and no Plan that is a &#8220;multiemployer plan&#8221; within the meaning of Section&nbsp;4001(a)(3) of ERISA is in &#8220;endangered status&#8221; or &#8220;critical status&#8221; (within the meaning of Sections 304 and 305 of ERISA)&nbsp;(v) the
fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no &#8220;reportable event&#8221; (within the meaning of
Section&nbsp;4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is reasonably expected to occur; (vii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code has received a favorable
determination letter, or is entitled to rely on an opinion letter, from the Internal Revenue Service, and, to the knowledge of the Company, nothing has occurred, whether by action or by failure to act, which would cause the loss of such
qualification; (viii)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit
Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a &#8220;multiemployer plan&#8221; within the meaning of Section&nbsp;4001(a)(3) of ERISA); and (ix)&nbsp;none of the following events has occurred or
is </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
reasonably likely to occur: (A)&nbsp;a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current
fiscal year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company&#8217;s and its Controlled Group affiliates&#8217; most recently completed fiscal year; or (B)&nbsp;a material increase
in the Company and its subsidiaries&#8217; &#8220;accumulated post-retirement benefit obligations&#8221; (within the meaning of Accounting Standards Codification Topic <FONT STYLE="white-space:nowrap">715-60)</FONT> compared to the amount of such
obligations in the Company and its subsidiaries&#8217; most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i)&nbsp;through (ix) hereof, as would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <I>Disclosure Controls</I>. The Company and its
subsidiaries maintain an effective system of &#8220;disclosure controls and procedures&#8221; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the requirements of the Exchange Act and that
has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the
Commission&#8217;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#8217;s management as appropriate to allow timely decisions regarding required disclosure.
The Company and its subsidiaries have conducted evaluations of the effectiveness of their disclosure controls as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act and such disclosure controls and procedures were
effective as of the end of the Company&#8217;s most recently completed fiscal quarter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <I>Accounting Controls.</I>
The Company and its subsidiaries maintain systems of &#8220;internal control over financial reporting&#8221; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that are designed to comply with the applicable
requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The Company and its subsidiaries maintain internal accounting controls sufficient to provide reasonable assurance that
(i)&nbsp;transactions are executed in accordance with management&#8217;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset
accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&#8217;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences; and (v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure
Package fairly presents the information called for in all material respects and is prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto. The Company&#8217;s internal control over financial reporting is
effective. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no material weaknesses in the Company&#8217;s internal </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
controls. The Company&#8217;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies and material weaknesses in the
design or operation of internal controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information; and
(ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal controls over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <I>Insurance. </I>The Company and its subsidiaries have insurance covering their respective properties, operations,
personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as generally maintained by similarly situated companies and which the Company believes are reasonably
adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i)&nbsp;received notice from any insurer or agent of such insurer that capital improvements or other
expenditures are required or necessary to be made in order to continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage at reasonable cost from similar insurers as may be necessary to continue its business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <I>Cybersecurity;
Data Protection. </I>The Company and its subsidiaries&#8217; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases owned or used by the Company or its subsidiaries
(collectively, &#8220;IT Systems&#8221;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted and as proposed to be
conducted in the Registration Statement, the Pricing Disclosure Package and the Prospectus, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries have
implemented and maintained commercially reasonable controls, policies, procedures, and safeguards designed to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT
Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (&#8220;Personal Data&#8221;)) collected, used, stored or processed in connection with their businesses, and, to the Company&#8217;s
knowledge, there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other person or entity, nor any incidents
under internal review or investigations relating to the same. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <I>Privacy</I>. (i)&nbsp;The Company and its
subsidiaries are presently in compliance with and, to their knowledge have complied with, all applicable laws or statutes (including without limitation, to the extent applicable, the Health Insurance Portability and Accountability Act of 1996, as
amended by the Health Information Technology for Economic and Clinical Health Act, the California Consumer Privacy Act, as amended by the California Privacy Rights Act, and the European Union General Data Protection Regulation and its equivalent in
the United Kingdom) and all applicable judgments, orders, rules </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
and regulations of any court or arbitrator or governmental or regulatory authority, approved final versions of external policies, and contractual obligations relating to the privacy and security
of IT Systems and the collection, use, transfer, import, export, storage, disposal and disclosure of Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification
(&#8220;Data Security Obligations&#8221;); (ii) neither the Company nor any of its subsidiaries have received any notification of or complaint regarding any <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Data Security Obligation;
(iii)&nbsp;there is no pending or, to the Company&#8217;s knowledge, threatened, action, suit or proceeding by or before any court or governmental agency, authority or body alleging <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any
Data Security Obligation; and (iv)&nbsp;the Company and its subsidiaries have made all disclosures as required by applicable laws and regulatory rules or requirements in connection with such Data Security Obligations, and no such disclosures have
been inaccurate or in violation of any applicable laws or regulatory rules and requirements, except in the case of each of (i)-(iv) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>No Unlawful Payments.</I> Neither the Company nor any of its subsidiaries nor any director,
officer or employee of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i)&nbsp;used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or
benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the
foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing
the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or
(iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or
benefit. The Company and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <I>Compliance with Anti-Money Laundering Laws</I>. The operations of the Company and its subsidiaries are and have
been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the U.S. Bank Secrecy Act, as amended by Title
III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), and the applicable money laundering statutes of all jurisdictions
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced
by any governmental agency (collectively, the &#8220;Anti-Money Laundering Laws&#8221;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its
subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <I>No Conflicts with Sanctions Laws. </I>Neither the Company nor any of its subsidiaries, directors, officers, or
employees, nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any sanctions administered or enforced by
the U.S. government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#8220;OFAC&#8221;) or the U.S. Department of State and including, without limitation, the designation as a
&#8220;specially designated national&#8221; or &#8220;blocked person&#8221;), the United Nations Security Council (&#8220;UNSC&#8221;), the European Union, His Majesty&#8217;s Treasury (&#8220;HMT&#8221;) or other relevant sanctions authority
(collectively, &#8220;Sanctions&#8221;), nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions broadly prohibiting dealings with such country or territory,
including, without limitation, Cuba, Iran, North Korea, the Crimea Region and the <FONT STYLE="white-space:nowrap">non-government</FONT> controlled areas of the Zaporizhzhia and Kherson Regions of Ukraine, the
<FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#8217;s Republic, the <FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#8217;s Republic, or any other Covered Region of Ukraine identified pursuant to Executive Order
14065 (each, a &#8220;Sanctioned Country&#8221;); and the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint
venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions except to the extent permitted for a
Person required to comply with Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in
the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. Since April&nbsp;24, 2019, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or transactions with
any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions prohibiting such dealing or transaction or with any Sanctioned Country. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <I>No Restrictions on Subsidiaries</I>. No subsidiary of the Company is currently prohibited, directly or indirectly,
under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#8217;s capital stock or similar ownership interest, from repaying to the
Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#8217;s properties or assets to the Company or any other subsidiary of the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <I>No Broker&#8217;s Fees.</I> Neither the Company nor any of its
subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder&#8217;s fee or like
payment in connection with the offering and sale of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <I>No Registration Rights</I>. No person has the
right to require the Company or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Shares, except for such
rights as have been duly waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <I>No Stabilization.</I> Neither the Company or any of its subsidiaries nor, to the
Company&#8217;s knowledge, other affiliates has taken, directly or indirectly, without giving effect to activities by the Underwriters, any action designed to or that would reasonably be expected to cause or result in any stabilization or
manipulation of the price of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <I>Margin Rules</I>. Neither the issuance, sale and delivery of the Shares
nor the application of the proceeds thereof by the Company as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve
System or any other regulation of such Board of Governors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <I>Forward-Looking Statements.</I> No forward-looking
statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been
made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <I>Statistical and
Market Data.</I> Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure
Package and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <I>Sarbanes-Oxley Act</I>. There is and has been no failure on the part of the Company or any of the Company&#8217;s
directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith (the &#8220;Sarbanes-Oxley Act&#8221;),
including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <I>Status under the
Securities Act</I>. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule
164(h)(2) under the Securities Act) of the Shares and at the date hereof, the Company was not and is not an &#8220;ineligible issuer,&#8221; as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this offering
pursuant to Rule 456(b)(1) under the Securities Act or will pay such fee within the time period required by such rule (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) [<I>Reserved</I>] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <I>Preclinical Studies and Clinical Trials. </I>The clinical and <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
trials conducted by or on behalf of or sponsored by the Company or any of its subsidiaries, or in which the Company or any of its subsidiaries has participated, that are described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, were, and if still pending are, being conducted in accordance with standard medical and scientific
research standards and procedures and all applicable statutes, rules and regulations of the FDA and other applicable regulatory authorities (collectively, the &#8220;Regulatory Authorities&#8221;) and current Good Clinical Practices and Good
Laboratory Practices; the descriptions in the Registration Statement, the Pricing Disclosure Package and the Prospectus of the results of such studies and tests are accurate and complete and fairly present the data derived from such trials; neither
the Company nor any of its subsidiaries has any knowledge of any other trials, the results of which are inconsistent with or call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package or the
Prospectus; the Company and each of its subsidiaries have operated at all times and are currently in compliance in all material respects with all applicable statutes, rules and regulations of the Regulatory Authorities; neither the Company nor any
of its subsidiaries has received any written notices, correspondence or other communications from the Regulatory Authorities or any other governmental agency requiring or threatening the termination, modification or suspension of any clinical or <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> trials that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, and, to the knowledge of the Company and its subsidiaries, there are no reasonable grounds for the same. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) <I>Regulatory Filings.</I> Neither the Company nor any of its subsidiaries has failed to file with the applicable
Regulatory Authorities any required filing, declaration, listing, registration, report or submission; all such filings, declarations, listings, registrations, reports or submissions were in compliance with applicable laws when filed; and no
deficiencies have been asserted by any applicable Regulatory Authority with respect to any such filings, declarations, listings, registrations, reports or submissions.<I> </I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx) <I>No Ratings.</I> There are (and prior to the Closing Date, will be) no debt securities, convertible securities or
preferred stock issued or guaranteed by the Company or any of its subsidiaries that are rated by a &#8220;nationally recognized statistical rating organization&#8221;, as such term is defined in Section&nbsp;3(a)(62) under the Exchange Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy) <I>XBRL</I>. The interactive data in eXtensible Business Reporting
Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(zz) <I>No Outstanding Loans or Other Indebtedness</I>. Except as described in the each of the Registration Statement, the
Pricing Disclosure Package and the Prospectus, there are no outstanding loans, advances (except normal advances for business expenses in the ordinary course of business) or guarantees or indebtedness by the Company to or for the benefit of any of
the officers or directors of the Company or any of the members of any of them. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aaa) <I>FINRA Exemption</I>. The Company
qualifies as an &#8220;experienced issuer&#8221; (within the meaning of FINRA Conduct Rule 5110(j)(6)) for purposes of exemption from filing under FINRA Conduct Rule 5110(h)(1)(C). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bbb) <I>Compliance with Laws</I>. The Company has not been advised and has no reason to believe, that it and each of its
subsidiaries are not conducting business in compliance with all applicable laws, rules and regulations of the jurisdictions in which it is conducting business, except where failure to do so in compliance would not result in a Material Adverse
Change. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ccc) <I>Export and Import Laws</I>. Each of the Company and its subsidiaries, and, to the Company&#8217;s
knowledge, each of their affiliates and any director, officer, agent or employee of, or other person associated with or acting on behalf of, the Company has acted at all times in compliance with applicable Export and Import Laws (as defined below)
and there are no claims, complaints, charges, investigations or proceedings pending or expected or, to the knowledge of the Company, threatened between the Company or any of its subsidiaries and any Governmental Authority under the Export or Import
Laws. The term &#8220;Export or Import Laws&#8221; means the Arms Export Control Act, the International Traffic in Arms Regulations, the Export Administration Act of 1979, as amended, the Export Administration Regulations, and all other laws and
regulations of the United States government regulating the provision of services to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> parties or the export and import of articles or information from and to the United States of America, and all
similar laws and regulations of any foreign government regulating the provision of services to parties not of the foreign country or the export and import of articles and information from and to the foreign country to parties not in the foreign
country. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ddd) <I>No Covered Foreign Person</I>. The Company is not a &#8220;covered foreign person,&#8221; as that term
is defined in 31 C.F.R. &#167; 850.209. The Company does not currently engage, or have plans to engage, directly or indirectly, in a covered activity. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Further Agreements of the Company</U>. The Company covenants and agrees with each
Underwriter that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Required Filings.</I> The Company will file the final Prospectus with the Commission within the
time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act; will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; and the Company will file promptly all reports and
any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of
a prospectus is required in connection with the offering or sale of the Shares; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York
City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representative may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Delivery of Copies.</I> The Company will deliver, without charge, (i)&nbsp;to the Representative, four signed copies of
the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii)&nbsp;to each Underwriter (A)&nbsp;a conformed copy
of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and supplements thereto
and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Representative may reasonably request. As used herein, the term &#8220;Prospectus Delivery Period&#8221; means such period of time after the first date
of the public offering of the Shares as in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act) in connection with
sales of the Shares by any Underwriter or dealer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Amendments or Supplements, Issuer Free Writing Prospectuses.</I>
Before making, preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure Package or the Prospectus,
whether before or after the time that the Registration Statement becomes effective, the Company will furnish to the Representative and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for
review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representative reasonably objects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Notice to the Representative.</I> The Company will advise the Representative promptly, and confirm such advice in
writing (which may be by electronic mail), (i) when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration Statement has been filed or becomes effective; (iii)&nbsp;when any supplement to the Pricing
Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or any amendment to the Prospectus has been filed
or distributed; (iv)&nbsp;of any request by the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration
Statement or any other request by the Commission for any additional information including, but not limited to, any request for information concerning any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication; (v)&nbsp;of the issuance by the Commission or any other governmental or regulatory authority of any order suspending the effectiveness
of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package, the Prospectus or any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or the initiation or threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (vi)&nbsp;of
the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, any of the Pricing Disclosure Package, any Issuer Free Writing Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in
the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package, any such Issuer Free Writing Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication is delivered to a purchaser, not misleading; and (vii)&nbsp;of the receipt by the Company of any notice with respect to any suspension of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or
threatening of any proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any
Preliminary Prospectus, any of the Pricing Disclosure Package or the Prospectus or any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or suspending any such qualification of
the Shares and, if any such order is issued, will obtain as soon as possible the withdrawal thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Ongoing
Compliance.</I> (1)&nbsp;If during the Prospectus Delivery Period (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a
material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or
supplement the Prospectus to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as
the Representative may designate such amendments or supplements to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or
supplemented (or any document to be filed with the Commission and incorporated by reference therein) will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will
comply with law and (2)&nbsp;if at any time prior to the Closing Date (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue
statement of a material fact or omit to state any material fact necessary in order to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or
supplement the Pricing Disclosure Package to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish to
the Underwriters and to such dealers as the Representative may designate such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so
that the statements in the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading or so that the Pricing Disclosure
Package will comply with law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Blue Sky Compliance.</I> The Company will qualify the Shares for offer and sale under
the securities or Blue Sky laws of such jurisdictions as the Representative shall reasonably request and will continue such qualifications in effect so long as required for distribution of the Shares; <U>provided</U> that the Company shall not be
required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent to service of process in any such
jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)
<I>Earning Statement. </I>The Company will make generally available to its security holders and the Representative as soon as practicable an earning statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of
the Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the &#8220;effective date&#8221; (as defined in Rule 158) of the Registration Statement,
provided that the Company will be deemed to have furnished such statements to its securityholders and the Representative to the extent they are filed on the Commission&#8217;s Electronic Data Gathering, Analysis and Retrieval system
(&#8220;EDGAR&#8221;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Clear Market.</I> For a period of 30 days after the date of the Prospectus (the
&#8220;Restricted Period&#8221;), the Company will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or
otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or exchangeable
for Stock, or publicly disclose the intention to undertake any of the foregoing, or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other
securities, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of the Representative, other than the Shares
to be sold hereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The restrictions described above do not apply to (i)&nbsp;the issuance
of shares of Stock or securities convertible into or exercisable for shares of Stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options (including net exercise) or the settlement
of RSUs (including net or settlement), in each case outstanding on the date of this Agreement and described in the Prospectus; (ii)&nbsp;grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of shares
of Stock or securities convertible into or exercisable or exchangeable for shares of Stock (whether upon the exercise of stock options or otherwise) to the Company&#8217;s employees, officers, directors, advisors, or consultants pursuant to the
terms of an equity compensation plan in effect as of the Closing Date and described in the Prospectus, provided that such recipients enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the Underwriters; (iii)&nbsp;the
issuance of up to 5% of the outstanding shares of Stock, or securities convertible into, exercisable for, or which are otherwise exchangeable for, Stock, immediately following the Closing Date, in connection with one or more acquisitions of a
company or a business, assets or technology of another person or entity, joint ventures, commercial relationships or strategic alliances (including but not limited to marketing or distribution arrangements, collaboration agreements or intellectual
property license agreements), provided that such recipients enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the Underwriters; (iv)&nbsp;the filing of any registration statement on Form
<FONT STYLE="white-space:nowrap">S-8</FONT> relating to securities granted or to be granted pursuant to any equity incentive plan or employee stock purchase plan in effect on the date of this Agreement and described in the Prospectus or any assumed
benefit plan pursuant to an acquisition or similar strategic transaction; or (v)&nbsp;the filing by the Company of any registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> or a successor form thereto relating to the
Company&#8217;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#8220;at-the-market&#8221;</FONT></FONT> offerings pursuant to that certain Sales Agreement between the Company and the Representative, dated January&nbsp;6, 2025.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Use of Proceeds.</I> The Company will apply the net proceeds from the sale of the Shares as described in each of
the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#8220;Use of Proceeds&#8221;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>No Stabilization.</I> Neither the Company nor its subsidiaries or affiliates will take, directly or indirectly, without
giving effect to activities by the Underwriters, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Exchange Listing.</I> The Company will use its reasonable best efforts to list for quotation the Shares on the Nasdaq
Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Reports.</I> During a period of three years from the date of this Agreement, the Company will furnish to
the Representative, as soon as commercially reasonable after the date that they are available, copies of all reports or other communications (financial or other) furnished to holders of the Shares, and copies of any reports and financial statements
furnished to or filed with the Commission or any national securities exchange or automatic quotation system; <U>provided</U> the Company will be deemed to have furnished such reports and financial statements to the Representative to the extent they
are filed on EDGAR. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Record Retention</I>. The Company will, pursuant to reasonable
procedures developed in good faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>Shelf Renewal</I>. If immediately prior to the third anniversary (the &#8220;Renewal Deadline&#8221;) of the initial
effective date of the Registration Statement, any of the Shares remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done so and is eligible to do so, a new automatic shelf registration
statement relating to the Shares, in a form satisfactory to the Representative. If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the Renewal Deadline, if it has not already done so, file a
new shelf registration statement relating to the Shares, in a form satisfactory to the Representative, and will use its best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Deadline. The
Company will take all other action necessary or appropriate to permit the issuance and sale of the Shares to continue as contemplated in the expired registration statement relating to the Shares. References herein to the Registration Statement shall
include such new automatic shelf registration statement or such new shelf registration statement, as the case may be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)
<I>Filings.</I> The Company will file with the Commission such reports as may be required by Rule 463 under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.
<U>Certain Agreements of the Underwriters</U>. Each Underwriter hereby represents and agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) It has not and will
not use, authorize use of, refer to or participate in the planning for use of, any &#8220;free writing prospectus&#8221;, as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission
by the Company and not incorporated by reference into the Registration Statement and any press release issued by the Company) other than (i)&nbsp;a free writing prospectus that contains no &#8220;issuer information&#8221; (as defined in Rule
433(h)(2) under the Securities Act) that was not included (including through incorporation by reference) in the Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex
A or prepared pursuant to Section&nbsp;3(c) or Section&nbsp;4(c) above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such underwriter and approved by the Company in advance in writing (each such free
writing prospectus referred to in clauses (i)&nbsp;or (iii), an &#8220;Underwriter Free Writing Prospectus&#8221;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It
has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains the final terms of the Shares unless such terms have previously been included in a free writing prospectus filed with the
Commission; <I>provided</I> that Underwriters may use a term sheet substantially in the form of Annex C hereto without the consent of the Company; <I>provided further</I> that any Underwriter using such term sheet shall notify the Company, and
provide a copy of such term sheet to the Company, prior to, or substantially concurrently with, the first use of such term sheet. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) It is not subject to any pending proceeding under Section&nbsp;8A of the
Securities Act with respect to the offering contemplated by this Agreement (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of Underwriters&#8217; Obligations.</U> The obligation of each Underwriter to purchase the Underwritten Shares on the Closing
Date or the Option Shares on the Additional Closing Date, as the case may be, as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Registration Compliance; No Stop Order.</I> No order suspending the effectiveness of the Registration Statement shall be
in effect, and no proceeding for such purpose or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with
the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all requests by the Commission for
additional information shall have been complied with to the reasonable satisfaction of the Representative. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<I>Representations and Warranties.</I> The representations and warranties of the Company contained herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be; and the
statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No Material Adverse Change.</I> No event or condition of a type described in Section&nbsp;3(h) hereof shall have
occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the
judgment of the Representative makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by
this Agreement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Officers&#8217; Certificate.</I> The
Representative shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer
of the Company who is satisfactory to the Representative, in their </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
respective capacities as officers of the Company and not in their personal capacities, (i)&nbsp;confirming that such officers have carefully reviewed the Registration Statement, the Pricing
Disclosure Package and the Prospectus and, to the knowledge of such officers, the representations set forth in Sections 3(b) and 3(d) hereof are true and correct, (ii)&nbsp;confirming that the other representations and warranties of the Company in
this Agreement are true and correct and that the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or the Additional Closing Date, as the case may
be, and (iii)&nbsp;to the effect set forth in paragraphs (a)&nbsp;and (c) above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>[Reserved]</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Comfort Letters.</I> On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the case
may be, Ernst&nbsp;&amp; Young LLP shall have furnished to the Representative, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably satisfactory to
the Representative, containing statements and information of the type customarily included in accountants&#8217; &#8220;comfort letters&#8221; to underwriters with respect to the financial statements and certain financial information contained or
incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date or the Additional Closing Date, as the case may be, shall use a <FONT
STYLE="white-space:nowrap">&#8220;cut-off&#8221;</FONT> date no more than two business days prior to such Closing Date or such Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Opinion of Intellectual Property Counsel for the Company. </I>Choate, Hall&nbsp;&amp; Stewart LLP, intellectual property
counsel for the Company, shall have furnished to the Representative, at the request of the Company, its written opinion, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and
substance reasonably satisfactory to the Representative. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT>
Statement of Counsel for the Company.</I> Cooley LLP, counsel for the Company, shall have furnished to the Representative, at the request of the Company, their written opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, dated the
Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representative. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> Statement of Counsel for the Underwriters.</I> The
Representative shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and <FONT STYLE="white-space:nowrap">10b-5</FONT> statement, addressed to the Underwriters, of Davis Polk&nbsp;&amp;
Wardwell LLP, counsel for the Underwriters, with respect to such matters as the Representative may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon
such matters. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>No Legal Impediment to Issuance and Sale.</I> No action shall have
been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as the case may
be, prevent the issuance or sale of the Shares; and no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or
sale of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Good Standing</I>. The Representative shall have received on and as of the Closing Date or the
Additional Closing Date, as the case may be, satisfactory evidence of the good standing of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing in such other jurisdictions as the Representative
may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Exchange Listing.</I> The Shares to be delivered on the Closing Date or the Additional Closing Date, as the case may be,
shall have been approved for listing on the Nasdaq Market, subject to official notice of issuance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I><FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The <FONT STYLE="white-space:nowrap">&#8220;lock-up&#8221;</FONT> agreements, each substantially in the form of Exhibit A hereto, between the Representative and certain shareholders, officers
and directors of the Company relating to sales and certain other dispositions of shares of Stock or certain other securities, delivered to the Representative on or before the date hereof, shall be full force and effect on the Closing Date or the
Additional Closing Date, as the case may be. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Additional Documents.</I> On or prior to the Closing Date or the
Additional Closing Date, as the case may be, the Company shall have furnished to the Representative such further certificates and documents as the Representative may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the
provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Indemnification
and Contribution</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of the Underwriters.</I> The Company agrees to indemnify and hold harmless each Underwriter,
its affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses, claims, damages
and liabilities (including, without limitation, reasonable and documented legal fees and other reasonable and documented expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are
incurred), joint or several, that arise out of, or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a
material </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fact required to be stated therein or necessary in order to make the statements therein not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained
in the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#8220;issuer information&#8221; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any
Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show as defined in Rule 433(h) under the Securities Act (a &#8220;road show&#8221;) or any Pricing Disclosure Package
(including any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under
which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in
conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representative expressly for use therein, it being understood and agreed that the only such information furnished by any
Underwriter consists of the information described as such in paragraph (b)&nbsp;below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of the Company.</I> Each
Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of
the Securities Act or Section&nbsp;20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities (including, without limitation, reasonable and
documented legal fees and other expenses incurred in connection with any suit, action, or proceeding or any claim asserted, as such fees and expenses are incurred) that arise out of, or are based upon, any untrue statement or omission or alleged
untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representative expressly for use in the Registration
Statement, the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT>
Communication, any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed upon that the only such information furnished by any Underwriter consists of
the following information in the Prospectus furnished on behalf of each Underwriter: the concession figures appearing in the eighth paragraph under the caption &#8220;Underwriting&#8221; and the information contained in the tenth and eleventh
paragraphs under the caption &#8220;Underwriting&#8221; relating to price stabilization, short positions and penalty bids. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notice
and Procedures.</I> If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding
paragraphs of this Section&nbsp;7, such person (the &#8220;Indemnified Person&#8221;) shall promptly notify the person against whom such indemnification may be sought (the &#8220;Indemnifying Person&#8221;) in writing; <U>provided</U> that the
failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under the preceding paragraphs of this Section&nbsp;7 except to the extent that it has been materially prejudiced (through the forfeiture of
substantive rights or defenses) by such failure; and <U>provided</U>, <U>further</U>, that the failure to notify the Indemnifying Person shall not relieve it </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;7. If any such proceeding shall be brought or asserted against an
Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel
to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and shall pay the reasonable and documented fees and
expenses in such proceeding and shall pay the reasonable and documented fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the
fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person has failed within a
reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those
available to the Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel
would be inappropriate due to actual or potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for
the reasonable and documented fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such reasonable and documented fees and expenses shall be paid or reimbursed as they are
incurred. Any such separate firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by TD Securities (USA) LLC and any such separate firm for the Company, its
directors, its officers who signed the Registration Statement and any control persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its
written consent, but if settled with such consent, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an
Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for reasonable and documented fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any
settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 60 days after receipt by the Indemnifying Person of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed
the Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in
respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person, in
form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure
to act by or on behalf of any Indemnified Person. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Contribution.</I> If the indemnification provided for in paragraphs (a)&nbsp;or (b)
above is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person
thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company,
on the one hand, and the Underwriters on the other, from the offering of the Shares or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative
benefits referred to in clause (i)&nbsp;but also the relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as
well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting
expenses) received by the Company from the sale of the Shares and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to
the aggregate offering price of the Shares. The relative fault of the Company, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material
fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent
such statement or omission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Limitation on Liability.</I> The Company and the Underwriters agree that it would not be just and
equitable if contribution pursuant to paragraph (d)&nbsp;above were determined by <U>pro</U> <U>rata</U> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take
account of the equitable considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d)&nbsp;above shall be deemed
to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of paragraphs (d)&nbsp;and (e), in no
event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Shares exceeds the amount of any
damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the
Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#8217; obligations to contribute pursuant to paragraphs (d)&nbsp;and (e) are several in proportion to their
respective purchase obligations hereunder and not joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies.</I> The
remedies provided for in this Section&nbsp;7 paragraphs (a)&nbsp;through (e) are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Effectiveness of Agreement</U>. This Agreement shall become effective as of the date
first written above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representative, by notice
to the Company, if after the execution and delivery of this Agreement and on or prior to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date (i)&nbsp;trading generally shall have been suspended or materially
limited on or by any of the New York Stock Exchange or The Nasdaq Stock Market; (ii)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (iv)&nbsp;there shall have occurred any outbreak
or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representative, is material and adverse and makes it impracticable or inadvisable to
proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Defaulting Underwriter</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If, on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to purchase the
Shares that it has agreed to purchase hereunder on such date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Shares by other persons satisfactory to the Company on the
terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such Shares, then the Company shall be
entitled to a further period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase such Shares on such terms. If other persons become obligated or agree
to purchase the Shares of a defaulting Underwriter, either the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full
business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company
agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term &#8220;Underwriter&#8221; includes, for all purposes of this Agreement unless
the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section&nbsp;10, purchases Shares that a defaulting Underwriter agreed but failed to purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be,
does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of Shares to be purchased on such date, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT>
Underwriter to purchase the number of Shares that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#8217;s pro rata share (based on the number of Shares that such Underwriter agreed to purchase on such date) of the
Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect to any arrangements for the purchase of the Shares of a
defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the Closing Date or
the Additional Closing Date, as the case may be, exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate amount of Shares to be purchased on such date, or if the Company shall not exercise the right described in paragraph
(b)&nbsp;above, then this Agreement or, with respect to any Additional Closing Date, the obligation of the Underwriters to purchase Shares on the Additional Closing Date, as the case may be, shall terminate without liability on the part of the <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without liability on the part of the Company, except that the Company will continue to be liable for the
payment of expenses as set forth in Section&nbsp;11 hereof and except that the provisions of Section&nbsp;7 hereof shall not terminate and shall remain in effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Payment of Expenses</U><I>.</I>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay
or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the Shares and any
transfer taxes payable in that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing
Disclosure Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the costs of reproducing and distributing each of the Transaction Documents; (iv)&nbsp;the fees and expenses
of the Company&#8217;s counsel and independent accountants; (v)&nbsp;the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Shares under the laws of such
jurisdictions as the Representative may designate and the preparation, printing and distribution of a Blue Sky Memorandum (including the reasonable and documented fees and expenses of counsel for the Underwriters);&nbsp;(vi) the cost of preparing
stock certificates; (vii)&nbsp;the costs and charges of any transfer agent and any registrar; (viii)&nbsp;all expenses and application fees incurred in connection with any filing with, and clearance of the offering by, FINRA (including the
reasonable and documented fees and expenses of counsel for the Underwriters), provided that the aggregate amount payable by the Company pursuant to this clause (viii)&nbsp;shall not exceed $10,000 (excluding filing fees); (ix) all expenses incurred
by the Company in connection with any &#8220;road show&#8221; presentation to potential investors (provided, however, that the Underwriters and the Company shall each pay 50% of the cost of chartering any aircraft to be used in connection with the
road show by the Company and the Underwriters); and (x)&nbsp;all expenses and application fees related to the listing of the Shares on the Nasdaq Market. It is understood, however, that except as provided in this Section&nbsp;11 or
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Section&nbsp;7 hereof, the Underwriters will pay their own costs and expenses, including the fees of their counsel, stock transfer taxes on the resale of any of the Shares owned by them, any
advertising expenses connected with any offers they may make and all travel (except as set forth in clause (ix)&nbsp;above), lodging and other expenses of the Underwriters, any of their employees, their representatives and counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If (i)&nbsp;this Agreement is terminated pursuant to (i)&nbsp;or (ii) of Section&nbsp;9, (ii) the Company for any reason fails to tender
the Shares for delivery to the Underwriters, or (iii)&nbsp;the Underwriters decline to purchase the Shares for any reason permitted under this Agreement, the Company agrees to reimburse the Underwriters for all reasonable and documented <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the reasonable and documented fees and expenses of their counsel) reasonably incurred by the Underwriters in connection with this
Agreement and the offering contemplated hereby; provided, however, that for purposes of this Section&nbsp;11(b), the Company shall in no event be liable to any of the Underwriters for any other amounts (for the avoidance of doubt, not including any
amounts under Section&nbsp;7 hereof), including, without limitation, damages on account of loss of anticipated profits from the sale of the Shares. For the avoidance of doubt, it is understood that the Company shall not pay or reimburse any costs,
fees or expenses incurred by any Underwriter that defaults on its obligations to purchase the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Persons Entitled to Benefit
of Agreement</U>. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each
Underwriter referred to in Section&nbsp;7 hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained
herein. No purchaser of Shares from any Underwriter shall be deemed to be a successor merely by reason of such purchase. For the avoidance of doubt, it is understood that the Company shall not pay or reimburse any costs, fees or expenses incurred by
any Underwriter that defaults on its obligations to purchase the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Survival</U>. The respective indemnities, rights of
contribution, representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant
hereto shall survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors,
officers, controlling persons or affiliates referred to in Section&nbsp;7 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Certain Defined Terms</U>. For purposes of this
Agreement, (a)&nbsp;except where otherwise expressly provided, the term &#8220;affiliate&#8221; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#8220;business day&#8221; means any day other than a day on which
banks are permitted or required to be closed in New York City; and (c)&nbsp;the term &#8220;subsidiary&#8221; has the meaning set forth in Rule 405 under the Securities Act. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Compliance with USA Patriot Act</U>. In accordance with the requirements of the USA
Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the
Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be
given to the Representative c/o TD Securities (USA) LLC, 1 Vanderbilt Avenue, 11th Floor, New York, New York 10017, Attention: Equity Capital Markets (email: CIBLegal@tdsecurities.com). Notices to the Company shall be given to it at Olema
Pharmaceuticals, Inc. 512 2nd Street, 4th Floor, San Francisco, California 94107; Attention: Sean Bohen (sean@olema.com), with a copy (which shall not constitute notice) to Cooley LLP, 3 Embarcadero Center, 20th Floor, San Francisco, California
94111, Attention: Yvan-Claude Pierre (ypierre@cooley.com) and Kristin VanderPas (kvanderpas@cooley.com). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Governing Law.</I> This
Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Submission to Jurisdiction</I>. The Company hereby submits to the exclusive jurisdiction of the U.S. federal and New York state courts
in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The Company waives any objection which it may now or hereafter have to the laying of
venue of any such suit or proceeding in such courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon the Company and may be enforced in any court to the
jurisdiction of which Company is subject by a suit upon such judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Waiver of Jury Trial.</I> Each of the parties hereto hereby
waives any right to trial by jury in any suit or proceeding arising out of or relating to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Recognition of the U.S.
Special Resolution Regimes</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event that any Underwriter that is a Covered Entity becomes subject to a
proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the
U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act
Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such
Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">As used in this Section&nbsp;16(g): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#8220;BHC Act Affiliate&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with,
12 U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#8220;Covered Entity&#8221; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) a &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#8220;Default Right&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167;
252.81, 47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#8220;U.S. Special Resolution Regime&#8221; means each of (i)&nbsp;the Federal Deposit Insurance
Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Counterparts.</I> This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of
telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S.
federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., <U>www.docusign.com</U>) or other transmission method and any counterpart so delivered shall be deemed to have
been duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Amendments or Waivers.</I> No amendment or waiver of
any provision of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Headings.</I> The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the
meaning or interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page follows]</I> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">Olema Pharmaceuticals, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Shane Kovacs</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Shane Kovacs</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">Title:&#8194;&#8201;&#8202;Chief Operating and Financial
Officer</P></TD></TR></TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted: As of the date first written above</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">TD SECURITIES (USA) LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">For itself and on behalf of the several Underwriters listed in Schedule 1 hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3">TD SECURITIES (USA) LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karen O&#8217;Reilly</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature page to Underwriting Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule 1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Underwriter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">TD Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Guggenheim Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LifeSci Capital LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Oppenheimer&nbsp;&amp; Co. Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">H.C. Wainwright&nbsp;&amp; Co., LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex A </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Disclosure Package</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Information Provided Orally by Underwriters</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="75%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Offering Price Per Share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$19.00</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Number of Shares:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">10,000,000 Underwritten Shares plus</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">1,500,000 Option Shares</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">ANNEX C </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Olema Pharmaceuticals, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>
Pricing Term Sheet </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><U>&#8195;&#8195;&#8195;&#8195;</U><U></U><U></U><U></U>, 2025 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TD SECURITIES (USA) LLC </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representative of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the several Underwriters listed in </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 to the
Underwriting </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreement referred to below </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o TD Securities
(USA) LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 Vanderbilt Avenue, 11th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New
York 10017 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Re: Olema Pharmaceuticals, Inc. &#8212; Public Offering </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned
understands that you, as Representative of the several Underwriters, propose to enter into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with Olema Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;),
providing for the public offering (the &#8220;Public Offering&#8221;) by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the &#8220;Underwriters&#8221;), of shares of common stock, par value $0.0001 per share, of the
Company (the &#8220;Common Stock&#8221;) and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase Common Stock (the <FONT STYLE="white-space:nowrap">&#8220;Pre-Funded</FONT> Warrants&#8221; and, together with the Common Stock, the
&#8220;Securities&#8221;). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the Underwriters&#8217; agreement to purchase and make the Public Offering of the Securities, and for other good and
valuable consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of TD Securities (USA) LLC ( the &#8220;Representative&#8221;) on behalf of the Underwriters, the undersigned will
not, and will not cause any direct or indirect affiliate to, during the period beginning on the date of this letter agreement (this &#8220;Letter Agreement&#8221;) and ending at the close of business 30 days after the date of the final prospectus
supplement relating to the Public Offering (the &#8220;Prospectus Supplement&#8221;) (such period, the &#8220;Restricted Period&#8221;), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock
(including without limitation, Common Stock or such other securities which may be </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a
stock option or warrant) (collectively with the Common Stock, <FONT STYLE="white-space:nowrap">&#8220;Lock-Up</FONT> Securities&#8221;), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of
the economic consequences of ownership of the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of
<FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, in cash or otherwise, (3)&nbsp;make any demand for or exercise any right with respect to the registration of any <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, or
(4)&nbsp;publicly disclose the intention to do any of the foregoing. The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions or arrangements (including, without
limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could
reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities, in cash or
otherwise. The undersigned further confirms that it has furnished the Representative with the details of any transaction the undersigned, or any of its affiliates, is a party to as of the date hereof, which transaction would have been restricted by
this Letter Agreement if it had been entered into by the undersigned during the Restricted Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, the
undersigned may: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;transfer the undersigned&#8217;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) as a bona fide gift or gifts, or for bona fide estate planning purposes, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) by will, other testamentary document or intestacy, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, or if the
undersigned is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust (for purposes of this Letter Agreement, &#8220;immediate family&#8221; shall mean any relationship by blood, current or former marriage,
domestic partnership or adoption, not more remote than first cousin), </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) to a partnership, limited liability company or
other entity of which the undersigned and/or the immediate family of the undersigned are the legal and beneficial owner of all of the outstanding equity securities or similar interests, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses
(i)&nbsp;through (iv) above, </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;if the undersigned is a corporation, partnership, limited
liability company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as
amended) of the undersigned, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the
undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B)&nbsp;as part of a distribution, transfer or disposition without consideration by the undersigned to its
stockholders, partners, members, beneficiaries or other equity holders, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) by operation of law, such as pursuant to a
qualified domestic order, divorce settlement, divorce decree, separation agreement or other court order, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) to the
Company (A)&nbsp;from an employee or other service provider of the Company upon death, disability or termination of employment or service, in each case, of such employee or service provider or (B)&nbsp;pursuant to an agreement under which the
Company has a right of first refusal with respect to transfers of such securities, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix) as part of a sale of the
undersigned&#8217;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities acquired in open market transactions after the closing date for the Public Offering, </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) to the Company in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants or
other rights to purchase shares of Common Stock (including, in each case, by way of &#8220;net&#8221; or &#8220;cashless&#8221; exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting,
settlement, or exercise of such restricted stock units, options, warrants or rights, <U>provided</U> that any such shares of Common Stock received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement, and
<U>provided further</U> that any such restricted stock units, options, warrants or rights are held by the undersigned pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or
plan which is described in the Registration Statement, the Pricing Disclosure Package and the Prospectus Supplement, or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi) pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by
the Board of Directors of the Company and made to all holders of the Company&#8217;s capital stock involving a Change of Control (as defined below) of the Company (for purposes hereof, &#8220;Change of Control&#8221; shall mean the transfer (whether
by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of
affiliated persons would hold more than 50% of the outstanding voting securities of the Company (or the surviving entity)); <U>provided</U> that in the event that such tender offer, merger, consolidation or other similar transaction is not
completed, the undersigned&#8217;s <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities shall remain subject to the provisions of this Letter Agreement; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>provided</U> that (A)&nbsp;in the case of any transfer or distribution pursuant to clauses (a)(i), (ii),
(iii), (iv), (v), (vi) and (vii), such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the Representative a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in
the form of this Letter Agreement, (B)&nbsp;in the case of any transfer or distribution pursuant to clause (a)(i), (iii), (iv), (v), (vi) and (ix), no filing by any party (donor, donee, devisee, transferor, transferee, distributer or distributee)
under the Exchange Act, or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on Schedule 13D, 13F or 13G, a Form 5 made after the expiration of the
Restricted Period referred to above or, in the case of (a)(i) only, a filing on Form 4 during the Restricted Period, each of which shall clearly indicate in the footnotes thereto the nature and conditions of such transfer) and (C)&nbsp;in the case
of any transfer or distribution pursuant to clause (a)(ii), (vii), (viii) and (x)&nbsp;it shall be a condition to such transfer that no public filing, report or announcement shall be voluntarily made and if any filing under Section&nbsp;16(a) of the
Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of Common Stock in connection with such transfer or distribution shall be legally required during the Restricted Period, such
filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) exercise
outstanding options, settle restricted stock units or other equity awards or exercise warrants pursuant to plans described in the Registration Statement, the Pricing Disclosure Package and the Prospectus Supplement; <U>provided</U> that any <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Securities received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) convert outstanding preferred stock, warrants to acquire preferred stock or convertible securities into shares of Common Stock or warrants
to acquire shares of Common Stock; <U>provided</U> that any such shares of Common Stock or warrants received upon such conversion shall be subject to the terms of this Letter Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) establish trading plans pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of shares
of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities; <U>provided</U> that (1)&nbsp;such plans do not provide for the transfer of <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities during the Restricted Period and (2)&nbsp;no filing
by any party under the Exchange Act or other public announcement shall be required or made voluntarily in connection with such trading plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the securities
described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All
authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. This Letter Agreement may be delivered via facsimile,
electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www. docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been
duly and validly delivered and be valid and effective for all purposes. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any
recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with respect to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and
tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Representative may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with
the Public Offering, the Representative and the other Underwriters are not making a recommendation to you to enter into this Letter Agreement, and nothing set forth in such disclosures is intended to suggest that the Representative or any
Underwriter is making such a recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned shall automatically be released from all obligations under this Letter
Agreement if: (A)&nbsp;the Underwriting Agreement does not become effective by November&nbsp;30, 2025; (B) if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment
for and delivery of the Common Stock to be sold thereunder; (C)&nbsp;either the Company, on the one hand, or the Representative, on the other hand, notifies the other in writing that it does not intend to proceed with the Public Offering; or
(D)&nbsp;the registration statement filed with the SEC in connection with the Public Offering is withdrawn. The undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Public Offering in
reliance upon this Letter Agreement. This Letter Agreement and any claim, controversy or dispute arising under or related to this Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page Follows] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Security Holder <I>(Print exact name)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">If not signing in an individual capacity:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Authorized Signatory <I>(Print)</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title of Authorized Signatory <I>(Print)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><I>(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</I></TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d46182dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 5.1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g46182dsp05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yvan-Claude Pierre </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 212
479 6721 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ypierre@cooley.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">November&nbsp;19, 2025 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Olema Pharmaceuticals, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">780 Brannan Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, California 94103 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Olema Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<B><I>Company</I></B>&#8221;), in connection with the offering by
the Company of 11,500,000 shares (the &#8220;<B><I>Shares</I></B>&#8221;) of its common stock, par value $0.0001 per share (the &#8220;<B><I>Common Stock</I></B>&#8221;), including up to 1,500,000 Shares that may be sold pursuant to the exercise of
an option to purchase additional Shares, pursuant to the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-284146)</FONT> (the &#8220;<B><I>Initial Registration
Statement</I></B>&#8221;) filed with the Securities and Exchange Commission (the &#8220;<B><I>Commission</I></B>&#8221;) by the Company under the Securities Act of 1933, as amended (the &#8220;<B><I>Securities Act</I></B>&#8221;), a related
registration statement on Form S-3 (File No. 333-291636) filed with the Commission on November 18, 2025, pursuant to Rule 462(b) under the Securities Act (together with the Initial Registration Statement, the &#8220;<B><I>Registration
Statements</I></B>&#8221;), the base prospectus included in the Initial Registration Statement (the &#8220;<B><I>Base Prospectus</I></B>&#8221;) and the prospectus supplement with respect to the Shares filed with the Commission pursuant to Rule
424(b) under the Securities Act (together with the Base Prospectus, the &#8220;<B><I>Prospectus</I></B>&#8221;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have
examined and relied upon the Registration Statements, the Prospectus, the Company&#8217;s certificate of incorporation and bylaws, each as currently in effect, and such other records, documents, opinions, certificates, memoranda and instruments as
in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all
documents submitted to us as copies; the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than the Company. As to certain factual
matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is expressed solely
with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any
federal or state securities law, rule or regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of the foregoing, in reliance thereon and subject to the assumptions, qualifications,
limitations and exceptions set forth herein, we are of the opinion that the Shares, when sold and issued against payment therefor in accordance with the Registration Statements and the Prospectus, will be validly issued, fully paid and
nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is limited to the matters expressly set forth in this letter, and no opinion has been or should be implied, or may be
inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we have no obligation or responsibility to update or supplement this letter to reflect any facts or
circumstances that may hereafter come to our attention or any changes in law that may hereafter occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 55 Hudson Yards New
York, New York 10001-2157 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (212) <FONT STYLE="white-space:nowrap">479-6000</FONT> f: (212)
<FONT STYLE="white-space:nowrap">479-6275</FONT> cooley.com </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g46182dsp05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Two <B></B> </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the heading &#8220;Legal Matters&#8221; in the Prospectus and
to the filing of this opinion as an exhibit to the Company&#8217;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the Commission for incorporation by reference into the Registration Statement. In giving such consents,
we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>C<SMALL>OOLEY</SMALL> LLP </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Yvan-Claude Pierre</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8201;Yvan-Claude Pierre</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 55 Hudson Yards New York, New York 10001-2157 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (212) <FONT STYLE="white-space:nowrap">479-6000</FONT> f: (212) <FONT STYLE="white-space:nowrap">479-6275</FONT> cooley.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>olma-20251119.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/20/2025 3:18:58 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:olma="http://olema.com/20251119"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://olema.com/20251119"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="olma-20251119_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="olma-20251119_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>olma-20251119_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/20/2025 3:18:58 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>olma-20251119_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/20/2025 3:18:58 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="olma-20251119.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g46182dsp05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g46182dsp05.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  W )\# 1$  A$! Q$!_\0
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MT;71?Y']6YUP/P_A,LQ6(HX:TX4YR3YYNS46T]96W[GZ-5]4?RD% !0 4 %
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MQU\?A_XT/5?F?V/Q%_R)<;_UZJ?^D,^]OVOOV@KKX,^%+33M"=%\3:QO$,S
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M/YQSK-*F<YA6QU3[;T79;)?)6,?XZ?!?2_CCX(ET2_?[)>1-Y]C?JNYK>8#
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M'[/G_!& XGDLRP590G);JTHR[/1K7HVG\KFG\8?VW]=^)^AS^&/"VAOH4&H
M6\TPF,]U.K<&- J@+NSMXW$CIC-77S"=:/LX*USCR'PZPF3UUCL?6]HX:I6Y
M8IKJ[MWMOT2\SVO]BW]GJ_\ A=I%[XG\1VWV7Q!JL2PPVCC]Y:VV0Q#>C.0I
M*]@JYYR!Z&7X5T4ZD]W^1^?>('%-+.:T,#@I7I4W=OI*6VGDE>SZW?2S.._;
M7_9SU;6-9_X6'X5M);V8QJNJ6ELI,P* !)T Y;Y0 V.1M!]2,,PPLI2]M35^
M_P#F>]X>\5X?#T?[&S"2BKOD;VUWB^VNJZ.[7:^!\.O^"A.HZ+H-O8>+/#QU
MN[@C"#4K6Y$3S8XS(A4C=CJ01D]JRI9I*,;5(W\ST\U\+J.(KRK9?7]G%N_*
MU=+T:>WDU\SS_P"*7QS\<_M9:YIOAC1M#>VL1*)(M(L7,Q=^GF32$ 87/4A5
M7))]:YJV)JXV2A%:=CZ?)N&\JX(H5,?BJUY6LYRTLNT5=ZOM=M]#[C_9\^$$
M7P3^&MEH!D2XU%W:ZO[B/.V2=@ =N?X5"JH]0N>]?186A]7IJ'7J?SIQ1GLN
M(<RGC+6@O=BNT5W\VVV_6Q^:/P/_ .2T^ /^Q@T__P!*8Z^2P_\ &AZK\S^N
MN(O^1+C?^O53_P!(9]J_MN? +4?B1HUAXK\.VC7NM:1$T-S:1+F6XMLEAL &
M69&+$+W#MCG /OYAAI54JD%JOR/Y\\.^)J.4UIY?C9<M*H[IO:,MM>RDK:]&
ME?35>4_!_P#;NU+P+X?MO#WC#0YM:6P06\-];RB.Y"* %21&&&(QC=D'@9!.
M37%0S*5.*A45['VF>^&U',L1+&9;65/GU<6KQN]6XM;)]K-=FE9#/&O[9?C_
M .+?B#2]$^&^D7.BR_:%>-+<BXNKHCH'^7:L?=A@CCEL9HJ8^M7DHT5;\RLO
MX!RC(\/4Q6=U545K._NQCZ:W<NSW[*Y]R>#SK9\+:4?$OV7^WC;H;T60(A$N
M/F"Y)X'2OHJ?/R+GWZG\YX_ZK]:J?4K^RN^7FWMTN>#?MV^ M/\ $GP<?7YI
M(K?4M!G22WD<@&1)'6-XL^^58#U05YN94E*CS]4?I7AMF=;"9PL)%-PK)IKL
MXIM2^6J]&>"?L%?"O_A*OB)=>+;R'=I_A],0%@</=2 A<=CM7<3Z$I7FY;1Y
MZGM'M'\S],\2\Z^I9?'+J;]^MOY16_WNR]$S]#*^H/Y;"@"MJ&G6FK6CVM]:
MPWEM(,/#<1AT;ZJ>#2:4E9HUI5:E&:G2DXM=4[,X63]GCX927'G'P)H(?KA;
M% O_ 'R!C]*YOJM"]^1'TBXISQ1Y?KE3_P "?Y[G::+H&F>&[%++2-.M-+LT
M^[;V4"PQCZ*H KHC&,%:*L?/XC$U\7-U<1-SD^LFV_O9?JCF.<\5_#GPMXZV
M?\)#X=TS66C&U)+VU21T'HK$9'X&LITJ=3XXIGJX+-<?EM_J=>5.^_+)I/U6
MS*_A7X4^#?!%P;C0?"^E:5<D8^T6UHBRX]-^,X_&IA0I4W>$4C7&YUF68QY,
M7B)S79R;7W;'5UN>*% '%>(?@IX!\5WSWNK>#]&O;R0[GN)+-!(Y]68#)_&N
M>6'HS=Y15SZ#"\09M@H*EA\5.,5LE)V7HMD;?AGP7H'@NU>VT#1=/T6!SETL
M+9(0Y]6V@9/UK2%.%-6@K'G8S,,7F$U/%U95&OYFW^9M5H<!R%C\'? 6F7MO
M>6?@CPY:7=O(LT-Q!I-NDD3J<JRL$R"" 01R"*P5"DG=07W(]VIGV;UH2IU,
M74E&2LTYR::>Z:OJF=?6YX1Q_B?X/^"/&=X;S6_"FD:E>'@W,]HAE8>A?&3U
M/4UA.A2J.\HIL]W!Y[FF7P]GA<3.$>RD[?=L:/A7P#X:\#0O%X>T'3M%23'F
M?8;9(C)C^\0,M^-5"E"G\$4CDQN9XW,9*6,K2J-;<S;MZ7V^1OUJ>:?#'_!0
M'XJ'5-<TGX?:=*9%LRM[J"1\[IG&(8SCN$8MC'_+1?2OG,SK7DJ*Z:L_HWPP
MR7V-"KG%=6YO=C?LOB?S>E_)GT]^SQ\+E^$7PHT;0G0+J+)]JU!@<[KA\%QG
MOMX0>R"O8PM'V%)1Z]?4_'^*<Y>>9K5Q:?N?#'_"MOOW?FSTFNL^2"@ H *
M"@ H * "@ H * "@ H * "@ H * "@!DI=8G,:AW )52< GL,]J!JS:OL?'_
M (!_9&\9W7QVB\=^/KW2;RV%Z^I20VD[RL\P.8DPT:@(IV_@@&*\&E@:KK^U
GK-;W/W;,^.,LAD3RG*(3B^503:2T^T])/5J_S=S[#KWC\("@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 19, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001750284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 19,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Olema Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">30-0409740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">780 Brannan Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">651-3316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OLMA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d46182d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d46182d8k.htm">d46182d8k.htm</File>
    <File>olma-20251119.xsd</File>
    <File>olma-20251119_lab.xml</File>
    <File>olma-20251119_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d46182d8k.htm": {
   "nsprefix": "olma",
   "nsuri": "http://olema.com/20251119",
   "dts": {
    "inline": {
     "local": [
      "d46182d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "olma-20251119.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "olma-20251119_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "olma-20251119_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-11-19_to_2025-11-19",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d46182d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-11-19_to_2025-11-19",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d46182d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://olema.com//20251119/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-25-288343-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-288343-xbrl.zip
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MM)L-IUI?Q^GO"!Q8[F >?B-!57E(?7(Q86X<\0=&K@<0OIC:8:1]<??V'"Z
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MS9P28+E?YU>5K],*Z[;FODA$[F:Z3S&RN<NQJZPWF52>O<&<7F]D6+@=K'3
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M=1[%-L FRJ]*PKT"WHP0X SN-CFI_>W^'.K3__PS6I]^AJ/]M2KS3?(BHRO
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MD7(?QPC;7Y]@]N'&DPABLO8 T)9U6,%H#,S$*)2YF#_4P=JD_R3/:D?QDUV
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M$FJM.A_NH9&B9B@%RMEML(5)'-=;5KC%Q0(/Z>QC=+0[^ 647]SU.\%_!TV
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M05HYF+3-.&)<>VDE%X/8ILK=;BX1*\3&L0BM*L+#9@JS5HI-*L&BT&QT2KK
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MR'> ;KA=!GY1!JH%L_YVJ?:W?^D-<LV;N_T@+7 R+A4\T4MT?>37V_I/EP*
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MEC\+N%HT#KK-QL%U4[^K7GPH,JE J91P-.%<QE-&Q/YX+$*I)FRTR.=HP1Z
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M'4VM7%M=:.5^';./GC'#BP"I9E+EI1U@A:$KY[C$K[HR/1'A=T)5G>AW[#O
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ML/=)KH_8)WO7'[;\"U!+ 0(4 Q0    ( )2*<UN"']F21A0  *1W   -
M          "  0    !D-#8Q.#)D.&LN:'1M4$L! A0#%     @ E(IS6Y(;
M36T;G0  <1@#  \              ( !<10  &0T-C$X,F1E>#$Q+FAT;5!+
M 0(4 Q0    ( )2*<UNZBNX(^ D  $HA   /              "  ;FQ  !D
M-#8Q.#)D97@U,2YH=&U02P$"% ,4    " "4BG-;^DG%(SL#   V"P  $0
M            @ '>NP  ;VQM82TR,#(U,3$Q.2YX<V102P$"% ,4    " "4
MBG-;[ZRT(%P&  "]0P  %0              @ %(OP  ;VQM82TR,#(U,3$Q
M.5]L86(N>&UL4$L! A0#%     @ E(IS6Z,C5?2P!   ;2H  !4
M     ( !U\4  &]L;6$M,C R-3$Q,3E?<')E+GAM;%!+!08     !@ & 'H!
(  "ZR@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d46182d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="olma-20251119.xsd" xlink:type="simple"/>
    <context id="duration_2025-11-19_to_2025-11-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001750284</identifier>
        </entity>
        <period>
            <startDate>2025-11-19</startDate>
            <endDate>2025-11-19</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-298">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-11-19_to_2025-11-19"
      id="Hidden_dei_EntityCentralIndexKey">0001750284</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-309">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-310">2025-11-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-311">Olema Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-312">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-313">001-39712</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-314">30-0409740</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-315">780 Brannan Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-316">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-317">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-318">94103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-319">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-320">651-3316</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-321">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-322">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-323">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-324">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-325">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-326">OLMA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-327">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-11-19_to_2025-11-19" id="ixv-328">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
